References

References:

1. Trulicity Physician prescribing information as approved by MO

2. Trulicity Instructions for Use as approved by MOH

3. Dungan KM, et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, noninferiority Trial. www.thelancet.com Published online July 11, 2014. 

4.  Wysham C, et al. Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide  in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1). Diabetes Care 2014;37:2159–2167.

5. Giorgino F, et al. Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients with Type 2 Diabetes on Metformin and Glimepiride (AWARD-2). Diabetes Care published online June 18,2015 (Ahead of print)

6. Weinstock RS, et al. Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study. Diabetes, Obesity and Metabolism 17: 849–858, 2015.

7. Matfin G, et al. Safe and Effective Use of the Once Weekly Dulaglutide Single-Dose Pen in Injection-Naïve Patients With Type 2 Diabetes. Journal of Diabetes Science and Technology 2015; 1–9.

8. Nauck M, et al. Diabetes Care. 2014;37(8):2149-2158

9. Pozzilli P, et al. Presented at 76^th Scientific Sessions of the American Diabetes Association; New Orleans, LA: June 10-14, 2016

10. Data on file, Lilly Research Laboratories (TRU20141009B)